Hepatic Biotransformation & CYP450 Drug-Drug Interactions (DDIs) (Clinical Treatise 2018)
Enzymatic transformation by the cytochrome P450 superfamily dictates oral first-pass clearance, bioactivation of prodrugs, and severe adverse drug-drug interactions.
Pharmacological Mechanism & Kinetic Schema
Mechanisms of CYP Inhibition: Reversible vs Quasi-Irreversible
Competitive inhibition occurs instantaneously when two co-administered drugs compete for the heme catalytic pocket (e.g., Fluconazole inhibiting CYP2C9, leading to toxic Warfarin accumulation). In contrast, mechanism-based (suicide) inhibition involves covalent binding of reactive metabolic intermediates to the apoprotein (e.g., Clarithromycin inactivating CYP3A4), requiring de novo enzyme synthesis over several days for clinical recovery.
Nuclear Receptor Activation and Transcriptional Enzyme Induction
Potent inducers like Rifampin and Carbamazepine bind to nuclear Pregnane X Receptor (PXR) and Constitutive Androstane Receptor (CAR). Translocation to the nucleus heterodimerizes with Retinoid X Receptor (RXR), massively upregulating CYP3A4, CYP2C9, and P-glycoprotein (ABCB1) transcription, causing therapeutic failure of oral contraceptives and calcineurin inhibitors.
Pharmacogenomic Polymorphisms: The CYP2D6 Spectrum
Genetic copy number variations and single nucleotide polymorphisms categorise patients from Poor Metabolizers (PMs, lacking codeine analgesia due to failure of morphine bio-activation) to Ultra-Rapid Metabolizers (UMs, facing life-threatening opioid toxicity under standard codeine doses).
Clinical Pharmacologist & Biochemist · Specialist in Pharmacokinetics & Hospital Pharmacotherapy · Published on November 14, 2018 at 01:35
